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Abstract
Background: Nuclear factor-kappa B (NF-kB) plays a role in prostate cancer and agents that suppress its activation may
inhibit development or progression of this malignancy. Alpha (a)-tomatine is the major saponin present in tomato
(Lycopersicon esculentum) and we have previously reported that it suppresses tumor necrosis factor-alpha (TNF-a)-induced
nuclear translocation of nuclear factor-kappa B (NF-kB) in androgen-independent prostate cancer PC-3 cells and also
potently induces apoptosis of these cells. However, the precise mechanism by which a-tomatine suppresses NF-kB nuclear
translocation is yet to be elucidated and the anti-tumor activity of this agent in vivo has not been examined.
Methodology/ Principal Findings: In the present study we show that suppression of NF-kB activation by a-tomatine occurs
through inhibition of I kappa B alpha (IkBa) kinase activity, leading to sequential suppression of IkBa phosphorylation, IkBa
degradation, NF-kB/p65 phosphorylation, and NF-kB p50/p65 nuclear translocation. Consistent with its ability to induce
apoptosis, a-tomatine reduced TNF-a induced activation of the pro-survival mediator Akt and its inhibition of NF-kB
activation was accompanied by significant reduction in the expression of NF-kB-dependent anti-apoptotic (c-IAP1, c-IAP2,
Bcl-2, Bcl-xL, XIAP and survivin) proteins. We also evaluated the antitumor activity of a-tomatine against PC-3 cell tumors
grown subcutaneously and orthotopically in mice. Our data indicate that intraperitoneal administration of a-tomatine
significantly attenuates the growth of PC-3 cell tumors grown at both sites. Analysis of tumor material indicates that the
tumor suppressing effects of a-tomatine were accompanied by increased apoptosis and lower proliferation of tumor cells as
well as reduced nuclear translocation of the p50 and p65 components of NF-kB.
Conclusion/ Significance: Our study provides first evidence for in vivo antitumor efficacy of a-tomatine against the human
androgen-independent prostate cancer. The potential usefulness of a-tomatine in prostate cancer prevention and therapy
requires further investigation.
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Introduction
Prostate cancer is the second most frequently diagnosed cancer
and the sixth leading cause of cancer death in men worldwide [1].
As progression of this malignancy is dependent on the androgen
receptor, therapies that target activating ligands (the hormones
testosterone and dihydrotestosterone) produce response rates in
patients of up to 95% [2]. Unfortunately, nearly all prostate cancer
patients develop hormone-refractory prostate cancer (HRPC) [2].
For these patients curative treatments are not available and
docetaxel-based chemotherapy provides palliation with response
rates of approximately 50% and median survival of 18 to 20
months with survival benefit of about 2 months [3]. For patients
with HRPC, low toxicity molecular targeting strategies are
needed.
Accumulating evidence suggests that the transcription factor
nuclear factor-kappa B (NF-kB) plays a pivotal role in prostate
cancer growth, survival, angiogenesis and metastatic progression
[4,5,6,7,8]. NF-kB consists of a p50/p65 heterodimer, that is
masked by the inhibitor of NF-kB, I kappa B alpha (IkBa) that
causes its retention in the cytoplasm under resting condition.
Various stimuli, including tumor necrosis-alpha (TNF-a), phorbol
ester and lipopolysaccharides (LPS), result in IkBa kinase
activation, which mediates IkBa phosphorylation at Ser32 and
Ser36 followed by its ubiquitination and proteasome-mediated
degradation. This releases the NF-kB p50/p65 heterodimer,
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which then translocates to the nucleus, where it binds to consensus
sequence motifs to induce gene transcription. It has been
demonstrated that NF-kB is constitutively activated in androgen-
insensitive prostate carcinoma cells, and overexpression of NF-kB
p65 protein was found in the nuclear fraction of prostate cancer
clinical specimens [5,9], suggesting a role for NF-kB in prostate
cancer progression. Consistently, it has been report that aberrant
IKK activation leads to the constitutive activation of the NF-kB
survival pathway in androgen-independent prostate cancer cells
[10]. In addition, activation and localization of NF-kB represent
independent risk factors for disease recurrence after radical
prostatectomy [9,11]. Hence, effective inhibition of NF-kB could
be a promising strategy for treatment of prostate cancer and
prevention of relapse.
Alpha (a)-tomatine is the major saponin in tomato (Lycopersicon
esculentum). Previous studies have reported its immunopotentiating
[12] and in vitro anti-cancer activities [13,14,15,16]. It also has
protective effects against dibenzo[a,l]pyrene (DBP)-induced liver
and stomach tumors in rainbow trout without causing significant
changes in total weight, liver weight, tissue morphology and
mortality [17]. Thus far, the mechanism by which a-tomatine
mediates its anti-prostate cancer effect is not well understood. Our
previous study reported the pro-apoptotic effect of a-tomatine
against androgen-independent human prostatic adenocarcinoma
PC-3 cells through the inhibition of TNF-a-induced NF-kB
nuclear translocation [18]. In the present study, the mechanism of
the inhibition of a-tomatine on NF-kB signaling pathway is further
characterized. For the first time, this study demonstrates the potent
anti-tumor activity of a-tomatine against human androgen-
independent prostate cancer in vivo.
Materials and Methods
Ethics statement
Experiments with mice were performed in accordance with the
protocol approved by the University of Queensland Animal Ethics
Committee (AEC Approval Number: MMRI/210/10).
Materials
a-tomatine was purchased from Tokyo Chemical Industry
(Tokyo, Japan). Dimethyl sulfoxide (DMSO), TNF-a, fetal bovine
serum (FBS), 3,3,5,5 tetramethylbenzidine (TMB), Calpain Inhib-
itor I, ALLN (N-acetyl-leucyl-leucyl-norleucinal) and anti-human
beta (b)-actin antibody were purchased from Sigma Aldrich (St.
Louis, MO). Penicillin/streptomycin, Roswell Park Memorial
Institute (RPMI-1640) media and 0.4% trypan blue solution were
purchased from Invitrogen (Carlsbad, CA). Protein A/G plus
agarose beads, Akt inhibitor VIII, and antibodies against p65, p50,
IkBa, Akt, IKKa, and IKKb were obtained from Santa Cruz
Biotechnology, CA. The glutathione S-transferase-IkBa (GST-
IkBa) fusion protein and polyvinylidene fluoride (PVDF) mem-
brane were purchased from Millipore (Bedford, MA). Kinase
buffer, antibodies against phospho-specific IkBa (Ser32/36),
phosphor-specific p65 (Ser536), phosphor-specific Akt (Ser473),
B cell leukaemia-2 (Bcl-2), B cell leukaemia-x long (Bcl-xL),
cellular inhibitor of apoptosis 1 (c-IAP1), cellular inhibitor of
apoptosis 2 (c-IAP2), survivin, X-linked inhibitor of apoptosis
(XIAP), histone H3 and cleaved-Poly (ADP-ribose) polymerase
(PARP) antibodies were purchased from Cell Signaling (Beverly,
MA). Antibodies against Ki-67 and proliferating cell nuclear
antigen (PCNA) were purchased from BD Biosciences (San Diego,
CA).
Cell line
The prostate cancer PC-3 cell line was purchased from the
American Type Culture Collection (Manassas, VA). Luciferase-
expressing prostate cancer PC-3 cell line was a kind gift of Dr.
Patrick Ming Tat Ling, Queensland University of Technology,
Australia [19,20]. Both PC-3 and luciferase-expressing PC-3 cells
were cultured in RPMI-1640 supplemented with 10% FBS,
100 U/mL penicillin and 100 mg/mL streptomycin. Cells were
cultured at 37uC in a 5% CO2 humidified incubator.
Cell treatment and fractionation
For the in vitro assays, PC-3 cells at 70-80% confluency were
treated with a-tomatine (2 mM) for 30 minutes, and then exposed
to10 ng/ml TNF-a for various time periods. Akt inhibitor VIII
(10 mM) which inhibits activation of Akt as evidenced by reduced
phosphorylation of this kinase at Thr308 and Ser473 [21] was
used as inhibitor control for studying the effect of a-tomatine on
Akt activation as described previously [22]. Both nuclear and
cytoplasmic fractions of treated and vehicle control cells were
isolated using a nuclear extraction kit (Cayman Chemical, Ann
Arbour, MI) according to the manufacturer’s instructions. Briefly,
cells were harvested using a cell scrapper then pelleted by
centrifugation at 4uC before two washes with ice-cold PBS
supplemented with phosphatase inhibitor solution at 4uC. Pelleted
cells were swollen for 15 minutes in ice-cold hypotonic buffer
supplemented with complete protease and phosphatase inhibitors.
10 % Nonidet P-40 assay reagent was then added and cytosolic
fractions were collected by brief centrifugation. Pellets were
resuspended in ice-cold complete nuclear extraction buffer then
vortexed on ice for 30 seconds at highest setting. These cell
pelleting and vortexing steps were repeated for a total of 6 cycles.
The final pellet was resuspended then centrifuged at 14,000 x g for
10 minutes at 4uC. The supernatants containing nuclear fractions
were collected.
Cell viability analysis
Cell viability was examined using a trypan blue exclusion assay
as described previously [23]. Briefly, cells in control and treated
groups were harvested, stained with 0.4% trypan blue solution and
total viable cells were counted using hemacytometer. The
proportion of viable cells was calculated by dividing the number
of viable test cells by the number of viable control cells at the end
of each experimental treatment.
IkBa kinase assay
The effect of a-tomatine on TNF-a-induced IKK activation was
analyzed as described previously [24]. Briefly, PC-3 cells were
preincubated with either 2 mM a-tomatine or 0.1% DMSO
(vehicle) for 30 minutes, and then treated with 10 ng/ml TNF-a
for the indicated times. IKK complex was immunoprecipitated
from whole cell extracts using antibodies against IKKa and IKKb.
Protein A/G plus agarose beads were added and incubated at 4uC
for overnight. The beads were washed with lysis buffer and
resuspended in a kinase buffer before GST-IkBa as IKK substrate
was added. After incubation at 30uC for 30 minutes, the reaction
was terminated by addition of Laemmli’s loading buffer and
heated at 100uC for 5 minutes. Western blot analysis was
performed to detect phosphorylated-IkBa (p-IkBa) and to
determine the total amounts of IKKa and IKKb in each sample.
To determine whether a-tomatine directly targets IKK, IKKa and
IKKb immunoprecipitated from 10 ng/ml TNF-a and 0.1%
DMSO (vehicle) treated cells. In vitro kinase assay was performed in
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the absence or presence of indicated concentrations of a-tomatine
at 30uC for 30 minutes.
Subcutaneous and orthotopic implantation of PC-3 cells
Male BALB/c nude mice (6 weeks old) were purchased from the
Animal Resources Centre (Canning Vale, Western Australia). For
subcutaneous tumor growth study, luciferase-expressing PC-3
prostate cancer cells (16106 in 0.1 ml Dulbecco’s PBS) were
inoculated subcutaneously into the lower flanks of each mouse. On
day 7 after cancer cell inoculation, each mouse had one palpable
tumor and were randomly assigned to four groups (n = 8/group).
These groups of mice were then given intraperitoneal injections of
vehicle solution, 10 mg/kg docetaxel, 5 mg/kg a-tomatine or
10 mg/kg a-tomatine thrice a week for an additional 3 weeks. All
the mice were monitored weekly for tumor growth and body
weight. Tumor dimensions were measured with calipers and
volume calculated using a standard formula: (length6width2)60.5
[25]. The experiment was terminated 28 days after cancer cell
inoculation at which time bioluminescent signals of tumors in live
mice were captured on a Xenogen IVIS Spectrum imaging system
(Alameda, CA, USA) using Live Imaging Acquisition and Analysis
software. Briefly, mice were injected intraperitoneally with
luciferin potassium salt, anesthetized and luminescence images
acquired. Luminescence signal intensity was quantified as region
of interest analysis of total photons per second for each tumor.
Tumors were excised, washed with ice-cold phosphate buffered
saline (PBS) and stored at -80uC until examined by Western blot
analysis.
Orthotopic growth of PC-3 cells was performed as described
previously [19]. Briefly, under a dissecting microscope (Olympus,
Tokyo, Japan), the prostate of 6 weeks old anesthetized SCID mice
were exposed through a surgical incision and 26105 cells in 10 ml
Dulbecco’s PBS injected into the dorsal prostate. Organs were
then replaced, and the abdomen was closed in two layers with silk
sutures. Five days after implantation, mice were randomly
assigned to two groups that received vehicle solution or 10 mg/
kg a-tomatine intraperitoneally thrice a week for 14 days (n = 6
per group). Body weight was measured weekly. Bioluminescent
signal of the PC-3 cell tumor in each mouse was measured at the
end of the study using a Xenogen IVIS Spectrum imaging system
as described above. All mice were then sacrificed by cervical
dislocation.
Tissue processing and protein extraction
For protein analysis of mouse tumors, tissues were minced,
suspended in tissue protein extraction reagent (Thermo-Fisher
Scientific, Waltham, MA) supplemented with complete protease
and phosphatase inhibitors, and homogenized using a gentle-
MACS Dissociator (Miltenyi Biotec, Germany). The homogenized
tissue was transferred to a pre-chilled microcentrifuge tube,
incubated on ice for 30 minutes and then centrifuged at 15,000
x g for 20 minutes at 4uC. The supernatant containing total
cellular proteins was collected for Western blot analysis. Nuclear
proteins were extracted using a nuclear extraction kit according to
the manufacturer’s instructions. Briefly, hypotonic buffer supple-
mented with 1 mM DTT and 0.01% Nonidet P-40 per gram of
tissues was added to minced tissues, which were then homogenized
with a gentleMACS Dissociator followed by incubation on ice for
15 minutes. Cytoplasmic proteins were separated by centrifuga-
tion. The pellets were resuspended in ice-cold complete nuclear
extraction buffer then vortexed on ice for 30 seconds at highest
setting. These cell pelleting and vortexing steps were repeated for a
total of 6 cycles. The suspensions were then centrifuged at 14,000
x g for 10 minutes at 4uC and supernatants containing nuclear
fractions were collected for Western blot analysis.
Western blot analysis
Protein samples were separated by SDS-PAGE and then
transferred onto PVDF membranes which were probed with
primary antibodies, followed after washes by horseradish perox-
idase-conjugated secondary antibodies and visualized colorimetri-
cally after further washes using TMB solution. Protein bands were
visualized and quantified using a gel documentation system
(BioRad, Richmond, Calif).
Statistical analysis
All assays were performed on at least three separate occasions.
Results are expressed as the mean value 6 standard error of the
mean (SEM). Statistical analysis was performed with one-way
analysis of variance, with Dunnett’s Multiple Comparison Test to
identify between-group differences using GraphPad Prism soft-
ware (version 5.0; GraphPad Software Inc., San Diego, CA). For in
vivo tumor growth experiments, statistical significance of differ-
ences in tumor volume, body weight and total bioluminescence
intensity between control and treatment groups was assessed by
two-way ANOVA (GraphPad Software Inc., version 5.0, San
Diego, CA), with p values , 0.05 considered significant. Statistical
significance is expressed as ***, p,0.001; **, p,0.01; *, p,0.05.
Results
a-tomatine inhibits TNF-a-induced nuclear translocation
of NF-kB p50 and p65 and phosphorylation of NF-kB p65
We previously showed that a-tomatine inhibited the growth of
androgen-independent human prostatic adenocarcinoma PC-3 in
vitro with the half maximal effective concentration (EC50) value of
1.676 0.3 mM [18]. At this chosen dose, a-tomatine was shown to
be less cytotoxic to human normal prostate RWPE-1 (EC50 3.856
0.1 mM) and normal liver WRL-68 cells (EC50 . 5 mM) [18].
Treatment with 2 mM a-tomatine induces apoptosis and inhibits
the TNF-a-induced NF-kB nuclear translocation on PC-3 cells
[18]. In the present study, the mechanism of a-tomatine in
inhibition of TNF-a-induced NF-kB nuclear translocation was
investigated by analyzing its effect on phosphorylation and
translocation of NF-kB sub-units in prostate cancer PC-3 cells.
As shown in Figure 1A, the time-dependent phosphorylation of
NF-kB p65 induced by TNF-a over a 60 minutes period was
completely suppressed by pretreatment of cells with 2 mM a-
tomatine. Examination of treated and control cell populations
using a trypan blue exclusion assay indicated that the concentra-
tion of a-tomatine and TNF-a used and the time of exposure had
minimal effect on cell viability (Figure 1B). In addition to the
observed loss of p65 phosphorylation, a-tomatine prevented TNF-
a induced translocation from the cytoplasm to the nucleus of both
p50 and p65 NF-kB sub-units (Figure 1C). These findings indicate
that a-tomatine inhibits the phosphorylation of NF-kB p65 and
prevents the nuclear translocation of NF-kB p50 and p65.
a-tomatine inhibits TNF-a-dependent IkBa
phosphorylation and degradation
The translocation of NF-kB to the nucleus is preceded by the
phosphorylation, ubiquitination and proteolytic degradation of
IkBa [26]. To determine whether the observed inhibition of TNF-
a-induced NF-kB nuclear translocation caused by a-tomatine was
due to inhibition of IkBa degradation, we pretreated cells with a-
tomatine and then exposed them to TNF-a stimulation for time
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periods up to 60 minutes. TNF-a induced IkBa degradation in
control cells as early as 5 minutes after stimulation (Figure 2A). In
contrast, in a-tomatine-pretreated cells, TNF-a stimulation did not
result in the degradation of IkBa, instead its expression was
sustained up to 60 minutes of treatment (Figure 2B). The effect of
a-tomatine on TNF-a-induced IkBa phosphorylation was exam-
ined using an antibody that detects IkBa phosphorylated at Ser32
and Ser36. Calpain inhibitor ALLN was used to prevent
degradation of phosphorylated IkBa. Western blot analysis
indicated that TNF-a induced IkBa phosphorylation as early as
5 minutes post-stimulation, but a-tomatine completely suppressed
this event (Figure 2B). These results indicate that a-tomatine
Figure 1. Effect of a-tomatine on TNF-a-induced phosphorylation of p65 and nuclear translocation of NF-kB p50/p65. (A) PC-3 cells at
70–80% confluency were treated with either 0.1% DMSO (vehicle) or 2 mM a-tomatine in DMSO for 30 minutes, followed by treatment with 10 ng/ml
TNF-a for the indicated times. Cytoplasmic extracts were analyzed by Western blot analysis using an antibody against the phosphorylated form of
p65. (B) Cell viability was assessed by counting cells that excluded trypan blue using a hemocytometer. (C) Effect of a-tomatine on nuclear and
cytoplasmic levels of NF-kB p50 and p65 in human prostate cancer PC-3 cells. Nuclear and cytoplasmic fractions extracted from PC-3 cells treated
either 0.1% DMSO or 2 mM a-tomatine in DMSO for 30 minutes, followed by treatment with 10 ng/ml TNF-a for the 30 minutes were analyzed by
Western blot analysis with antibodies against NF-kB p50 and p65 proteins. b-actin and histone H3 proteins were loading control for cytoplasmic and
nuclear extracts, respectively. Graphical representation of densitometry analysis of NF-kB p50 and p65 Western blot analyses from three independent
experiments are shown below each panel. The ratio of the signal intensity of each protein to loading control was normalized to the vehicle control. *
P,0.05, ** P,0.01, *** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0057708.g001
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Figure 2. Effect of a-tomatine on IkBa Kinase activity. (A) Cells were grown to 70–80 % confluence, treated with either 0.1% DMSO (vehicle) or
2 mM a-tomatine in DMSO for 30 minutes, followed by treatment with 10 ng/ml of TNF-a for the indicated times. The presence of IkBa was detected
by Western blot analysis. (B) To determine whether a-tomatine inhibits IkBa degradation by blocking IkBa phosphorylation, cells were treated with
either 0.1% DMSO (vehicle) or 2 mM a-tomatine in DMSO for 30 minutes, followed by 50 mg/ml calpain inhibitor ALLN for 30 minutes, and then
treated with 10 ng/ml of TNF-a for the times indicated. Anti-phospho-IkBa Western blot analysis was performed on cytoplasmic extracts. b-actin
served as a loading control. (C) PC-3 cells were preincubated with either 2 mM a-tomatine or 0.1% DMSO (vehicle) for 30 minutes, and then treated
with 10 ng/ml TNF-a for the indicated times. IKKa and IKKb were immunoprecipitated from lysates from cells and in vitro kinase assays were
performed using GST-IkBa as substrate as described in ‘‘Materials and Methods’’. Western blot analysis was performed to detect phosphorylated IkBa.
Antitumor Activity of Alpha-Tomatine
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inhibited TNF-a-induced phosphorylation and degradation of
IkBa and subsequent nuclear translocation of NF-kB.
a-tomatine inhibits TNF-a-induced IKK activation
TNF-a induces IkBa phosphorylation and degradation via
activation of the IKK complex [26]. To determine if pretreatment
with a-tomatine affects IKK activation, in vitro kinase assays were
performed using immunoprecipitated components of the IKK
complex, and GST-IkBa as the IKK phosphorylation substrate.
As shown in Figure 2C, TNF-a treatment stimulated IKK activity
as phosphorylated-IkBa was detected as early as 5 minutes after
treatment and remained detectable 10 minutes later. In contrast,
phosphorylated-IkBa was not detected in cells treated with 2 mM
a-tomatine during the 15 minutes period of TNF-a stimulation
(Figure 2C). Western blot analysis demonstrated that TNF-a and
a-tomatine had no effect on the expression of the components of
the IKK complex, IKKa or IKKb (Figure 2C), indicating that a-
tomatine blocked TNF-a-induced phosphorylation of IkBa by
attenuating the action of IKK rather than by causing degradation
of this kinase. In a second set of experiments, we assessed whether
a-tomatine suppressed IKK activity by directly binding to IKK
protein by using IKKa and IKKb immunoprecipitated from cells
treated with TNF-a. The kinase reaction mixture was incubated
with increasing concentrations of a-tomatine (1, 2 and 5 mM). As
shown in Figure 2D, whereas TNF-a caused an increase in
phosphorylation of IkBa, this was not reduced by inclusion of
increasing concentrations of a-tomatine. This suggests that while
a-tomatine efficiently inhibits IKK-mediated phosphorylation of
IkBa, it did not do this by directly inhibiting IKK.
a-tomatine inhibits TNF-a-induced Akt activation
It has been reported that the serine-threonine kinase Akt can
activate IKK [27]. To gain insight into whether this pathway may
be relevant in TNF-a–induced activation of NF-kB signaling, we
pretreated PC-3 cells with 2 mM a-tomatine for 30 minutes then
exposed these cells to TNF-a for time periods up to 15 minutes. In
control experiments cells were treated with an Akt inhibitor, Akt
inhibitor VIII, at 10 mM for 3 hours as described previously [22].
As shown in Figure 2E, TNF-a induced Akt activation in a time-
dependent manner and a-tomatine suppressed this activation as
effectively as Akt inhibitor VIII with no significant effect on the
expression of total Akt protein.
a-tomatine represses TNF-a-induced NF-kB dependent
expression of pro-survival proteins
Several studies have indicated that the transcription factor NF-
kB regulates the expression of proteins implicated in facilitating
tumor cell survival including Bcl-2, Bcl-xL, c-IAP, survivin and
XIAP [28,29]. Accordingly, we next examined whether a-
tomatine inhibition of TNF-a-induced NF-kB nuclear transloca-
tion is accompanied by alterations in the expression of these pro-
survival proteins. In these experiments cells were pretreated with
a-tomatine (2 mM) for 30 minutes before induction of TNF-a-
induced effects for 6 hours. This time period was selected to
permit accumulation of levels of pro-survival proteins sufficient for
Western blot analysis. As during this time period a-tomatine
treatment resulted in varying levels of cell rounding and
detachment in treated and control cells, both adherent and non-
adherent cells were collected for protein extraction. As shown in
Figure 3 Western blot analysis revealed that TNF-a induced
marked upregulation of c-IAP1 and c-IAP2 while increases in
expression of Bcl-xL, survivin and XIAP were also apparent but at
lower levels and Bcl-2 expression was marginally increased in
response to this cytokine. It was striking that a-tomatine caused
sharp down-regulation of each of these mediators of cell survival
under basal conditions as well as completely blocking TNF-a-
induced upregulation of each protein (Figure 3). These data
indicate that, consistent with its ability to inhibit TNF-a-induced
NF-kB nuclear translocation, a-tomatine blocks the expression of
the pro-survival mediators typically upreguated by this cytokine.
(D) IKK complex immunoprecipitated from vehicle and TNF-a-treated PC-3 cell extracts with an anti-IKKa and IKKb antibodies was assayed for IKK
activity. The kinase reaction mixture was incubated with a-tomatine as indicated. The expressions of phosphorylated IkBa and IKK were examined by
Western blot analysis using anti-phospho-IkBa, anti-IKKa and anti-IKKb antibodies. To examine the basal level of expression of IKK proteins, whole-cell
extracts analyzed by Western blotting using anti-IKKa and anti-IKKb antibodies. (E) PC-3 cells were pretreated with 2 mM a-tomatine for 30 minutes,
and then treated with 10 ng/ml TNF-a for the indicated times. Lysates extracted from cells treated with 10 mM Akt inhibitor VIII for 3 hours serve as
inhibition control. Cytoplasmic extracts were used for Western blotting using anti-phosphospecific Akt (Ser473) antibody. The same blot was
reprobed with nonphosphorylated Akt antibody. Graphical representation of densitometry analysis of phosphor-Akt Western blot analysis from three
independent experiments is shown below the panel. The ratio of the signal intensity of each protein to loading control was normalized to the vehicle
control. * P,0.05, ** P,0.01, *** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0057708.g002
Figure 3. a-tomatine represses TNF-a-induced NF-kB depen-
dent expression of pro-survival proteins. PC-3 cells grown to 70–
80 % confluence were treated with either 0.1% DMSO or 2 mM a-
tomatine for 30 minutes, 10 ng/ml TNF-a was then added and the cells
were incubated for a further 6 hours. Whole-cell extracts were
prepared, and were analyzed by Western blot analysis using antibodies
against Bcl-2, Bcl-xL, c-IAP1, c-IAP2, XIAP and survivin. The results shown
here are representative of three independent experiments.
doi:10.1371/journal.pone.0057708.g003
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a-tomatine attenuates growth of PC-3 cell xenograft
tumors in mice
To examine the effect of a-tomatine on tumor growth in vivo, we
challenged PC-3 cell tumors grown subcutaneously in mice. In
these experiments tumors were allowed to establish for 1 week
before challenge 3 times per week for 3 weeks with a-tomatine (5
or 10 mg/kg/mouse), the prostate cancer therapeutic docetaxel
(10 mg/kg/mouse) [30] and vehicle solution. Figure 4A shows that
10 mg/kg a- tomatine was as efficient as 10 mg/kg docetaxel at
retarding growth of PC-3 cell subcutaneous mouse tumors. In
addition, there was also a marked decrease in tumor volume in
response to lower dose of a-tomatine (5 mg/kg). Specifically, 3
weeks after the commencement of drug challenge the average
tumor volume in vehicle control mice (1000 6 180 mm3), was
approximately 1.4 fold higher as compared to mice treated with
5 mg/kg a-tomatine (720 6 60 mm3), and approximately 4.7 fold
higher compared with mice treated with 10 mg/kg of a-tomatine
(210 6 35 mm3) or docetaxel (183 6 32 mm3) (Figure 4A). Of
note, a-tomatine treatment at both 5 mg/kg (Figure 4B, blue) and
10 mg/kg (Figure 4B, green) did not provoke body weight loss in
contrast with docetaxel (Figure 4B, red) which caused a reduction
in body weight of ,10% more than those seen in untreated tumor
bearing mice (Figure 4B, black). In fact, both control and
docetaxel treatment groups showed a trend of decreasing body
weight after 14 days of cancer cells inoculation, potentially due to
high tumor burden and toxicity of docetaxel, respectively (Figure
4B). Consistent with the tumor volumes determined from caliper
measurements, the intensity of bioluminescence measured on day
28 was significantly lower in both docetaxel and 10 mg/kg a-
tomatine treatment groups (Figure 4C and D). These results
suggest that a-tomatine retards the growth of PC-3 cell
subcutaneous xenograft tumors at an effective dose of 10 mg/kg.
We also used an orthotopic mouse model to examine the effect
of a-tomatine on prostate tumor growth. In this experiment, PC-3
cell tumors were allowed to grow in mice for 5 days before thrice
weekly treatment for 2 weeks with 10 mg/kg a-tomatine. As
Figure 4. Anti-tumor activity of a-tomatine against subcutaneous PC-3 cell tumors. Luciferase expressing PC-3 cell xenograft tumors
established in male nude mice (n = 8 per treatment group) for 1 week were treated thrice weekly for 3 weeks with vehicle, docetaxel (10 mg/kg) or
a-tomatine (5 or 10 mg/kg). (A) Graph of tumor volume in each treatment group versus the number of days after initial injection of PC-3 cells. (B)
Graph of mean body weight for each treatment group versus the number of days after initial injection of PC-3 cells. (C) Bioluminescence intensities
emitted from PC-3 cell xenograft tumors at the end of the experiment for each treatment group. (D) Bioluminescence images of PC-3 subcutaneous
xenografts. The first row shows the vehicle control group; middle row shows the docetaxel treatment group; bottom row shows the 10 mg/kg a-
tomatine treatment group. Each bar or point represents the mean 6 SEM of data (n = 8).* P,0.05, ** P,0.01, *** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0057708.g004
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shown in Figure 5A, and consistent with the data obtained from
the xenograft mouse model, a-tomatine significantly suppressed
the tumorigenicity of PC-3 cell orthotopic tumors. In addition, the
total body weight of mice was not adversely affected by a-tomatine
treatment (Figure 5B). The images in Figure 5C shows strong
bioluminescent signal from the prostate of control mice, demon-
strating that the tumor cells were successfully implanted. In
addition, 4 out of 6 a-tomatine treated mice showed only weak
bioluminescent signals and another 2 mice had no signal. These
findings demonstrate that a-tomatine has potent anti-tumor effects
against mouse xenograft and orthotopic PC-3 cell tumors.
a-tomatine reduces expression of proliferation markers,
increases expression of apoptosis markers and inhibits
nuclear translocation of NF- kB in xenograft tumors
To examine the mechanism by which a-tomatine suppressed
the growth of PC-3 cell tumors in mice, we next examined tumor
tissue recovered from mice carrying subcutaneous tumors for
expression of markers of proliferation (PCNA and Ki-67) and
apoptosis (cleaved-PARP and cleaved-caspase-3). This analysis
was not possible for orthotopic tumors as insufficient material was
available for the a-tomatine treated mice. As shown in Figure 6,
Western blot analysis of lysates from six independent tumor
samples indicated that while both markers of proliferation (PCNA
and Ki-67) decreased in response to a-tomatine treatment (Figure
6A and B), levels of both markers of apoptosis (cleaved-PARP and
caspase-3) increased (Figure 6C and D). These data suggest that
both anti-proliferative and pro-apoptotic effects of a-tomatine
contribute to the reduced growth of PC-3 cell tumors in mice. As
NF-kB translocation to the nucleus is important for promoting
increased cell proliferation and survival and we have shown that
this translocation event is reduced in vitro by a-tomatine, we were
interested to examine recovered subcutaneous mouse tumors for
localization of NF-kB. As shown in Figure 6E, Western blot
analysis from six independent tumor samples indicated that there
was a distinct decrease in the levels of NF-kB components in the
nucleus of tumor cells in response to a-tomatine treatment. These
data suggest that the anti-tumor effects of a-tomatine in vivo may
be due to its ability to block the proliferative and anti-apoptotic
Figure 5. Anti-tumor activity of a-tomatine against orthotopic PC-3 cell tumors. Luciferase expressing PC-3 cell orthotopic tumors
established in male SCID mice (n = 6 per treatment group) for 5 days were treated thrice weekly for 2 weeks with vehicle or a-tomatine (10 mg/kg).
(A) Bioluminescence intensities emitted from PC-3 cell orthotopic tumors for each treatment group after 14 days of treatment. (B) Bioluminescent
images at the end of the experiment of SCID mice carrying orthotopic tumors of luciferase expressing PC-3-luc cells. The upper row shows the vehicle
control group, whereas the bottom row shows the a-tomatine (10 mg/kg) treatment group. (C) Graph of mean body weight for each treatment
group versus the number of days after initial injection of PC-3 cells. Each bar or point represents the mean6 SEM of data (n = 6).* P,0.05, ** P,0.01,
*** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0057708.g005
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effects of NF-kB signaling by reducing its translocation to the
nucleus.
Discussion
We provide the first evidence that the saponin a-tomatine can
efficiently inhibit the growth of prostate cancer tumors in vivo
without inducing overt toxicity. Our analysis of recovered mouse
tumors suggest that mechanistically a-tomatine mediates its anti-
prostate cancer effects in vivo by blocking, at least in part, the
proliferative and anti-apoptotic effects of NF-kB signaling by
reducing translocation of this protein complex to the nucleus. Our
detailed in vitro analyses indicate that a-tomatine suppression of
NF-kB activation occurs through indirect inhibition of IKK kinase
activity, leading to suppression of IkBa phosphorylation and
degradation, NF-kB/p65 phosphorylation and NF-kB p50/p65
nuclear translocation. Consistent with its ability to induce
apoptosis, a-tomatine inhibition of NF-kB activation in vitro was
accompanied by significant reduction in expression of TNF-a
induced pro-survival mediators c-IAP, Bcl-2, Bcl-xL, survivin and
XIAP.
The NF-kB signaling pathway is an important target for disease
treatment because its dysregulation is required for inappropriate
inflammatory responses as well as cancer and other ailments [31].
In response to most activating stimuli, NF-kB signaling occurs
through sequential activation of IKK, phosphorylation of IkBa at
serine 32 and 36, leading to its degradation, and the nuclear
translocation of NF-kB where it regulates transcription of a range
of genes including those that promote cell proliferation and
survival [32]. Consistent with our data from a-tomatine,
suppression of NF-kB activation has been shown to be a critical
mechanism of action of several plant-derived anticancer agents,
such as curcumin, lycopene, silibinin, genistein, resveratrol and
green tea polyphenols [33]. In the present study, we showed that
a-tomatine is an indirect inhibitor of IKK. Presumably, a-
tomatine inhibits upstream signaling components that lead to
activation of the IKK complex, such as Akt serine-threonine
kinase , NF-kB inducing kinase, mitogen-activated protein kinase
kinase kinase (MEKK)1, MEKK3, TGF activated kinase 1
(TAK1) and glycogen synthase kinase-3 beta [34,35,36,37,38].
Indeed, we found that a-tomatine inhibits TNF-a-induced Akt
activation, although further experiments are needed to address if
this effect is responsible for the changes we observed in
phosphorylation and translocation of NF-kB components or the
anti-tumor actions of a-tomatine against subcutaneous and
orthotopic tumors grown in mice. These results are in agreement
with those of previous studies that suggest that a-tomatine
suppresses invasion and migration of human lung cancer cells in
vitro through the inhibition of the Akt [15,16]. As conventional
chemotherapeutic agents, including docetaxel target normal as
well as tumor cells and lead to deleterious effects for prostate
cancer patients there is a pressing need to identify less toxic agents
to control this disease. In recent years, a number of naturally
occurring dietary agents of reduced toxicity have been reported to
induce apoptosis and inhibit tumor growth, highlighting the
promise of using naturally derived agents for chemotherapy and
chemoprevention of prostate and other cancers [39,40,41].
Furthermore, it is also possible that an inhibitor of NF-kB
activation could be an adjuvant for overcoming tumor resistance
to radiation and chemotherapies, such as paclitaxel, doxorubicin,
5-fluorouracil, and vinca alkaloids (vinblastine and vincristine),
that occur via NF-kB activation [42,43,44]. It is thought that this
induced resistance in a wide variety of tumor cells occurs via
induction of NF-kB effector genes, including Bcl-2 [45], Bcl-xL
[46], survivin [47], XIAP [48], c-IAP1 [49] and c-IAP2 [49] that
are known to mediate protective responses to chemotherapeutic
agents and radiation. Therefore, targeting NF-kB through the
actions of a-tomatine, which we have shown to block NF-kB
activation and transcription of NF-kB effector genes, may result in
improvements in treatment of prostate cancer. In support of this,
other dietary agents, including resveratrol, curcumin, genistein,
(2) epigallocatechin gallate and soya isoflavone that can block
various steps leading to NF-kB activation and sensitize tumor cells
to the beneficial effects of chemotherapeutic drugs and radiation in
treatment of cancer [50,51,52,53,54,55,56].
We previously reported that a-tomatine induces caspase-
dependent death of PC-3 cells in vitro accompanied by increased
caspase-3 activity and the release of cytochrome c [18]. Caspases
have been shown to be involved in apoptosis through activation of
PARP downstream molecule [57]. Importantly, here we have
demonstrated the pro-apoptotic effect of a-tomatine in vivo by
showing a significant increase in the cleavage of PARP and
caspase-3 in a-tomatine-treated tumors. In addition, our data
show that a-tomatine elicits anti-proliferative effects in vivo as we
observed reduced levels of the markers of proliferation Ki-67 and
PCNA. Our data from PC-3 tumors also suggest that these pro-
apoptotic and anti-proliferative effects of a-tomatine are mediated,
at least in part, by reduced nuclear translocation of NF-kB p50
and p65. Indeed our in vitro studies clearly demonstrate that a-
tomatine is very effective at blocking activation and translocation
of the components of the NF-kB complex providing support for
the possibility that this mechanism is also important for its effects in
vivo against prostate cancer PC-3 cell tumors.
In summary, we present the first evidence that a-tomatine is an
effective anti-tumor compound against prostate cancer xenograft
and orthotopic tumors. This agent may prove to be useful in the
prevention and treatment of androgen-independent prostate
cancer and this warrants further investigation.
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Figure 6. Western blot analysis of PCNA, Ki-67, cleaved-PARP, cleaved-caspase-3 and NF-kB in PC-3 tumor tissues samples. (A–D) PC-
3 tumors excised from mice treated with vehicle, 5 mg/kg or 10 mg/kg of a-tomatine were lysed and examined by Western blot analysis.
Representative images are shown. Markers of proliferation (PCNA and Ki-67). Markers of apoptosis (cleaved PARP and cleaved caspase-3). b-actin was
used as loading control. (E) Western blot analysis on nuclear extracts probing for NF-kB p50 and p65 levels. Equal loading of protein was confirmed
by stripping and reprobing the blots with histone H3 antibody. Graphical representation of densitometry analysis of each Western blot data from six
independent tumor samples is shown below each panel. The ratio of the signal intensity of each protein to loading control was normalized to the
vehicle control. * P,0.05, ** P,0.01, *** P,0.001 vs vehicle control.
doi:10.1371/journal.pone.0057708.g006
Antitumor Activity of Alpha-Tomatine
PLOS ONE | www.plosone.org 10 February 2013 | Volume 8 | Issue 2 | e57708
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer
statistics. CA Cancer J Clin 61: 69–90.
2. Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, et al. (2005)
Cancer of the prostate. Crit Rev Oncol Hematol 56: 379–396.
3. Dagher R, Li N, Abraham S, Rahman A, Sridhara R, et al. (2004) Approval
summary: Docetaxel in combination with prednisone for the treatment of
androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 10:
8147–8151.
4. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ (2001) Blockade of
NF-kappaB activity in human prostate cancer cells is associated with suppression
of angiogenesis, invasion, and metastasis. Oncogene 20: 4188–4197.
5. Surh J, Payvandi F, Edelstein L, Amenta P, Zong W, et al. (2002) Mechanisms of
constitutive NF-kB activation in human prostate cancer cells. Prostate 52: 183–
200.
6. Yemelyanov A, Gasparian A, Lindholm P, Dang L, Pierce JW, et al. (2006)
Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis
and invasion activity in prostate carcinoma cells. Oncogene 25: 387–398.
7. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, et al. (2008) The nuclear factor-
kappaB pathway controls the progression of prostate cancer to androgen-
independent growth. Cancer Res 68: 6762–6769.
8. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, et al.
(2004) Nuclear factor-kappaB is constitutively activated in prostate cancer in
vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocar-
cinoma of the prostate. Clin Cancer Res 10: 5501–5507.
9. Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM, et al. (2004)
Nuclear factor-kappaB nuclear localization is predictive of biochemical
recurrence in patients with positive margin prostate cancer. Clin Cancer Res
10: 8460–8464.
10. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, et al. (2002)
The role of IKK in constitutive activation of NF-kappaB transcription factor in
prostate carcinoma cells. J Cell Sci 115: 141–151.
11. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, et al.
(2005) Activation of nuclear factor-kappaB in human prostate carcinogenesis
and association to biochemical relapse. Br J Cancer 93: 1285–1294.
12. Morrow WJ, Yang YW, Sheikh NA (2004) Immunobiology of the Tomatine
adjuvant. Vaccine 22: 2380–2384.
13. Friedman M, Lee KR, Kim HJ, Lee IS, Kozukue N (2005) Anticarcinogenic
effects of glycoalkaloids from potatoes against human cervical, liver, lymphoma,
and stomach cancer cells. J Agric Food Chem 53: 6162–6169.
14. Friedman M, Levin CE, Lee SU, Kim HJ, Lee IS, et al. (2009) Tomatine-
containing green tomato extracts inhibit growth of human breast, colon, liver,
and stomach cancer cells. J Agric Food Chem 57: 5727–5733.
15. Shieh JM, Cheng TH, Shi MD, Wu PF, Chen Y, et al. (2011) alpha-Tomatine
Suppresses Invasion and Migration of Human Non-Small Cell Lung Cancer
NCI-H460 Cells Through Inactivating FAK/PI3K/Akt Signaling Pathway and
Reducing Binding Activity of NF-kappaB. Cell Biochem Biophys 60: 297–310.
16. Shih YW, Shieh JM, Wu PF, Lee YC, Chen YZ, et al. (2009) Alpha-tomatine
inactivates PI3K/Akt and ERK signaling pathways in human lung adenocar-
cinoma A549 cells: effect on metastasis. Food Chem Toxicol 47: 1985–1995.
17. Friedman M, McQuistan T, Hendricks JD, Pereira C, Bailey GS (2007)
Protective effect of dietary tomatine against dibenzo[a,l]pyrene (DBP)-induced
liver and stomach tumors in rainbow trout. Mol Nutr Food Res 51: 1485–1491.
18. Lee ST, Wong PF, Cheah SC, Mustafa MR (2011) Alpha-tomatine induces
apoptosis and inhibits nuclear factor-kappa B activation on human prostatic
adenocarcinoma PC-3 cells. PLoS ONE 6: e18915.
19. Luk SU, Lee TK, Liu J, Lee DT, Chiu YT, et al. (2011) Chemopreventive effect
of PSP through targeting of prostate cancer stem cell-like population. PLoS One
6: e19804.
20. Luk SU, Yap WN, Chiu YT, Lee DT, Ma S, et al. (2011) Gamma-tocotrienol as
an effective agent in targeting prostate cancer stem cell-like population. Int J
Cancer 128: 2182–2191.
21. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, et al. (2005)
Identification and characterization of pleckstrin-homology-domain-dependent
and isoenzyme-specific Akt inhibitors. Biochem J 385: 399–408.
22. Estrada AC, Syrovets T, Pitterle K, Lunov O, Buchele B, et al. (2010) Tirucallic
acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing
apoptosis in prostate cancer cells. Mol Pharmacol 77: 378–387.
23. Husain K, Francois RA, Yamauchi T, Perez M, Sebti SM, et al. (2011) Vitamin
E delta-tocotrienol augments the antitumor activity of gemcitabine and
suppresses constitutive NF-kappaB activation in pancreatic cancer. Mol Cancer
Ther 10: 2363–2372.
24. Sethi G, Ahn KS, Pandey MK, Aggarwal BB (2007) Celastrol, a novel
triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor
cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated
NF-kappaB activation. Blood 109: 2727–2735.
25. Plymate SR, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, et al. (2003)
Increased manganese superoxide dismutase (SOD-2) is part of the mechanism
for prostate tumor suppression by Mac25/insulin-like growth factor binding-
protein-related protein-1. Oncogene 22: 1024–1034.
26. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M (1997) The
IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and
IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation.
Cell 91: 243–252.
27. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, et al. (1999) NF-kappaB
activation by tumour necrosis factor requires the Akt serine-threonine kinase.
Nature 401: 82–85.
28. Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:
203–208.
29. Plati J, Bucur O, Khosravi-Far R (2011) Apoptotic cell signaling in cancer
progression and therapy. Integr Biol (Camb) 3: 279–296.
30. Tang Y, Parmakhtiar B, Simoneau AR, Xie J, Fruehauf J, et al. (2011) Lycopene
enhances docetaxel’s effect in castration-resistant prostate cancer associated with
insulin-like growth factor I receptor levels. Neoplasia 13: 108–119.
31. Sethi G, Tergaonkar V (2009) Potential pharmacological control of the NF-
kappaB pathway. Trends Pharmacol Sci 30: 313–321.
32. Karin M, Lin A (2002) NF-kappaB at the crossroads of life and death. Nat
Immunol 3: 221–227.
33. Gupta SC, Sundaram C, Reuter S, Aggarwal BB (2010) Inhibiting NF-kappaB
activation by small molecules as a therapeutic strategy. Biochim Biophys Acta
1799: 775–787.
34. Aggarwal BB, Takada Y, Shishodia S, Gutierrez AM, Oommen OV, et al.
(2004) Nuclear transcription factor NF-kappa B: role in biology and medicine.
Indian J Exp Biol 42: 341–353.
35. Hoeflich K, Luo J, Rubie E, Tsao M, Jin O, et al. (2000) Requirement for
glycogen synthase kinase-3 beta in cell survival and NF kappaB activation.
Nature 406: 86–90.
36. Lee F, Peters R, Dang L, Maniatis T (1998) MEKK1 activates both IkappaB
kinase alpha and IkappaB kinase beta. Proc Natl Acad Sci U S A 95: 9319–9324.
37. Sakurai H, Miyoshi H, Toriumi W, Sugita T (1999) Functional interactions of
transforming growth factor beta-activated kinase 1 with IkappaB kinases to
stimulate NF-kappaB activation. J Biol Chem 274: 10641–10648.
38. Yang J, Lin Y, Guo Z, Cheng J, Huang J, et al. (2001) The essential role of
MEKK3 in TNF-induced NF-kappaB activation. Nat Immunol 2: 620–624.
39. Cragg GM, Grothaus PG, Newman DJ (2009) Impact of natural products on
developing new anti-cancer agents. Chem Rev 109: 3012–3043.
40. Khan N, Adhami VM, Mukhtar H (2010) Apoptosis by dietary agents for
prevention and treatment of prostate cancer. Endocr Relat Cancer 17: R39–52.
41. Nobili S, Lippi D, EwaWitort, Donninic M, Bausi L, et al. (2009) Natural
compounds for cancer treatment and prevention. Pharmacological Research 59:
365–378.
42. Das KC, White CW (1997) Activation of NF-kappaB by antineoplastic agents.
Role of protein kinase C. J Biol Chem 272: 14914–14920.
43. Uetsuka H, Haisa M, Kimura M, Gunduz M, Kaneda Y, et al. (2003) Inhibition
of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in
human stomach cancer cell line. Exp Cell Res 289: 27–35.
44. Wang W, McLeod HL, Cassidy J (2003) Disulfiram-mediated inhibition of NF-
kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal
cancer cell lines. Int J Cancer 104: 504–511.
45. Catz SD, Johnson JL (2001) Transcriptional regulation of bcl-2 by nuclear factor
kappa B and its significance in prostate cancer. Oncogene 20: 7342–7351.
46. Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, et al. (1999) Tumor
necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation
in primary hippocampal neurons. J Biol Chem 274: 8531–8538.
47. Zhu L, Fukuda S, Cordis G, Das DK, Maulik N (2001) Anti-apoptotic protein
survivin plays a significant role in tubular morphogenesis of human coronary
arteriolar endothelial cells by hypoxic preconditioning. FEBS Lett 508: 369–374.
48. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, et al. (1998)
Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expres-
sion protects endothelial cells from tumor necrosis factor alpha-induced
apoptosis. J Exp Med 188: 211–216.
49. Gill C, Dowling C, O’Neill AJ, Watson RW (2009) Effects of cIAP-1, cIAP-2 and
XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell
survival and proliferation. Mol Cancer 8: 39.
50. Akimoto T, Nonaka T, Ishikawa H, Sakurai H, Saitoh JI, et al. (2001) Genistein,
a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal
cancer cell lines in vitro: possible involvement of inhibition of survival signal
transduction pathways. Int J Radiat Oncol Biol Phys 50: 195–201.
51. Fulda S, Debatin KM (2004) Sensitization for anticancer drug-induced apoptosis
by the chemopreventive agent resveratrol. Oncogene 23: 6702–6711.
52. Komatsu K, Tauchi H, Yano N, Endo S, Matsuura S, et al. (1997) Inhibitory
action of (-)-epigallocatechin gallate on radiation-induced mouse oncogenic
transformation. Cancer Lett 112: 135–139.
53. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A,
et al. (2009) Curcumin sensitizes human colorectal cancer to capecitabine by
modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an
orthotopic mouse model. Int J Cancer 125: 2187–2197.
54. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, et al. (2005) Inactivation of nuclear
factor kappaB by soy isoflavone genistein contributes to increased apoptosis
induced by chemotherapeutic agents in human cancer cells. Cancer Res 65:
6934–6942.
55. Sandur SK, Deorukhkar A, Pandey MK, Pabon AM, Shentu S, et al. (2009)
Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing
Antitumor Activity of Alpha-Tomatine
PLOS ONE | www.plosone.org 11 February 2013 | Volume 8 | Issue 2 | e57708
constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys 75:
534–542.
56. Zoberi I, Bradbury CM, Curry HA, Bisht KS, Goswami PC, et al. (2002)
Radiosensitizing and anti-proliferative effects of resveratrol in two human
cervical tumor cell lines. Cancer Lett 175: 165–173.
57. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG (1993)
Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of
chemotherapy-induced apoptosis. Cancer Res 53: 3976–3985.
Antitumor Activity of Alpha-Tomatine
PLOS ONE | www.plosone.org 12 February 2013 | Volume 8 | Issue 2 | e57708
